"Rapid growth in our understanding of the elegance and complexity of human biology to address human suffering due to molecular defects inspired me to become a doctor and focus on translational oncology. Molecular diagnostics, the evolution of biologics, and new targeted therapeutics are transforming the diagnosis, treatment, and monitoring of cancer. This is an incredibly exciting time to be in personalized medicine.

I have had the honor of spending much of my professional career at Genomic Health. It is a great privilege to be part of our pioneering mission to develop and commercialize high-quality, clinically-actionable diagnostics with the end goal of improving patient outcomes and helping turn cancer into a manageable, and ultimately preventable disease. This is not just a passion for our incredible team, but a responsibility. I am proud to be a part of it."
Dedicated to improving cancer care through the development of innovative and clinically actionable diagnostics, Rick Baehner, M.D., has served cancer patients for more than 20 years at the University of California, San Francisco and Genomic Health. Rick began his career at Genomic Health 17 years ago and quickly assumed various leadership roles, most recently as Vice President of Development Oncology and Pathology. Over the years Rick has led teams that worked on the development of Genomic Health’s innovative tests including the Oncotype DX Breast Recurrence Score test; quantitative single gene reporting for ER, PR and HER-2 status; the Oncotype DX Colon Recurrence Score test; the Oncotype DX Genomic Prostate Score (GPS) test; and the Oncotype DX DCIS (ductal carcinoma in situ) Score, which was selected by Time Magazine as one of the year’s leading medical breakthroughs in 2012. Rick is a faculty member at the University of California, San Francisco where he completed his residency and multiple fellowships. He directed the Hellen Diller Cancer Center, Immunohistochemistry Core Laboratory for over a decade. Rick holds Bachelor of Arts and M.D. degrees from the University of Kansas.
Oncotype DX My Colon Cancer Coach